AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV)

Today's Latest Price: $90.11 USD

0.48 (0.54%)

Updated Sep 18 7:00pm

Add ABBV to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 232 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABBV Stock Summary

  • ABBV has a higher market value than 99.03% of US stocks; more precisely, its current market capitalization is $159,029,123,797.
  • ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 0.59% of US stocks.
  • In terms of volatility of its share price, ABBV is more volatile than only 4.19% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to AbbVie Inc, a group of peers worth examining would be AMGN, AZN, LLY, CSCO, and NVO.
  • Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to
ABBV Daily Price Range
ABBV 52-Week Price Range

ABBV Stock Price Chart Technical Analysis Charts

ABBV Price/Volume Stats

Current price $90.11 52-week high $101.28
Prev. close $89.63 52-week low $62.55
Day low $88.86 Volume 10,076,304
Day high $90.50 Avg. volume 10,025,920
50-day MA $94.66 Dividend yield 5.24%
200-day MA $89.17 Market Cap 159.03B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$90.11$229.97 157%

Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 66th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 158% on a DCF basis. The most interesting components of our discounted cash flow analysis for AbbVie Inc ended up being:

  • The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 22.77% of free cash flow generating stocks in the Healthcare sector.
  • AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 6.07% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See QDEL, HZNP, LXRX, HCSG, and AHPI.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

Income Investors: Boost Your Income Using Call Options

Article Thesis With interest rates at an extremely low level, investors have to hunt for yield elsewhere, especially when they are living off the income their assets generate, e.g. in retirement. Dividend-paying stocks are one possibility to generate a sizeable yield on one's investment, but options can be another way...

Jonathan Weber on Seeking Alpha | September 16, 2020

AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

AbbVie Inc. (ABBV) Morgan Stanley 18th Annual Global Healthcare Conference September 16, 2020 11:00 AM ET Company Participants Rick Gonzalez - Chairman & Chief Executive Officer Mike Severino - Vice Chairman & President Rob Michael - Executive Vice President & Chief Financial Officer Conference Call Participants Dave Risinger - Morgan...

SA Transcripts on Seeking Alpha | September 16, 2020

Malin Akerman Joins CoolSculpting® and CoolTone™ as U.S. Ambassador for the Allergan Aesthetics Body Contouring Portfolio

Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the partnership between actress and producer Malin Akerman and the Allergan Aesthetics body contouring portfolio. Akerman is named the first Allergan Aesthetics body contouring partner in support of both CoolSculpting®, the 1 nonsurgical fat reduction treatment used most by doctors, and CoolTone™, the latest treatment in the portfolio used to strengthen, tone, and firm the abdomen, buttocks, and thigh muscles.

Yahoo | September 16, 2020

The Argus Dividend Growth Portfolio

Often overlooked amid the market's gyrations, dividend income is an important element of total return. Consider recent results: in 2015, the S&P 500 delivered a total return of 1.4%, including dividends -- but excluding dividends, the market was down 0.7%. Capital gains were a bit easier to achieve in 2016-17, though we note that dividend payments still contributed about 15%-20% of total return for investors. And dividend payments softened the blow in 2018, when most market indices declined as the Federal Reserve hiked rates. Between 1930 and 2012, dividend income accounted for 42% of total return of the S&P 500, according to Morgan Stanley. Not all dividends are created equal, though, and it is important to understand the difference between high-yield stocks and dividend-growth sto...

Yahoo | September 16, 2020

Great Yield and Packed Pipeline Signal a Buy for AbbVie

Investors can still own AbbVie stock at a good price, even in the wake of a potentially lifesaving collaboration.

InvestorPlace | September 15, 2020

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo -5.01%
3-mo -6.23%
6-mo 37.16%
1-year 31.49%
3-year 18.64%
5-year 93.79%
YTD 5.96%
2019 1.47%
2018 -0.96%
2017 60.07%
2016 9.79%
2015 -6.50%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7304 seconds.